circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
== Research == Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It was created by Tanox under the code name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a phase II clinical trial for the treatment of asthma.
== Career == In 1996 Davidson proposed that the level of a person's HbA1c—a measure of average blood glucose—could be used to diagnose diabetes mellitus. The American Diabetes Association and the World Health Organization agreed in 2010 and recommended its use for diagnosis. Davidson is a past president of the American Diabetes Association, a past Editor-in-Chief of Diabetes Care and the founding editor of Current Diabetes Reports. He is the author of more than 170 scientific articles. Wiley Medical Education published Davidson's first book, Diabetes Mellitus: Diagnosis and Treatment, in four editions beginning in 1981. Saunders (now Elsevier) published a fifth edition co-authored by Anne Peters Harmel and Ruchi Mathur, in 2003, renaming the book Davidson's Diabetes Mellitus: Diagnosis and Treatment. The American Diabetes Association published Meeting the American Diabetes Association Standards of Care: An Algorithmic Approach to Clinical Care of the Diabetes Patient in 2010. The title is in its second edition, published in 2017. With Debra L. Gordon, Davidson wrote two editions of The Complete Idiot's Guide to Type 2 Diabetes. In 1970 Philip Rossman and Mayer Davidson founded the Venice Family Clinic, a free clinic in the Venice neighborhood of Los Angeles. By the mid-1990s, it had grown to be the largest free medical clinic in the country. It is now a UCLA-affiliated community clinic with 12 locations. He is now chief medical officer of Mellitus Health.
== In popular culture == In Winter Light (1963), directed by Ingmar Bergman, the church sexton Algot Frövik was modeled on prop master K.A. Bergman, whose Bekhterev's disease (ankylosing spondylitis) served as the basis for the character's illness. The Oxbow Cure (2013) follows Lena, a woman recently diagnosed with ankylosing spondylitis as she comes to terms with the disease while living in rural Ontario.
== Pests and diseases == Witches' broom (Moniliophthora perniciosa) is the most prominent disease that affects cupuaçu trees. It affects the entire tree and can result in significant loss of yields and even tree death if left untreated. Regular pruning is recommended to reduce the severity of this disease in cupuaçu plantings. Cupuaçu supports the butterfly herbivore, "lagarta verde", Macrosoma tipulata (Hedylidae), which can be a defoliator.
Sources: en.wikipedia.org
A 2017 study in The BMJ by Tim Dyson and Valeria Cetorelli concluded that "Saddam Hussein's government successfully manipulated the 1999 survey in order to convey a very false impression." In the case of Cuba, a declassified 1960 U.S. State Department memorandum by diplomat Lester D. Mallory argued that "every possible means should be undertaken promptly to weaken the economic life of Cuba" by denying money and supplies in order "to bring about hunger, desperation and overthrow of government." A 2025 study funded by the Center for Economic and Policy Research, authored by Mark Weisbrot, Francisco Rodríguez, and Silvio Rendón and published in The Lancet, estimated that unilateral sanctions by all parties—including those of the United States, United Nations, and European Union—were associated with as many as 564,258 deaths annually between 1971 and 2021. The study found "significant causal association between sanctions and increased mortality" with "the strongest effects for unilateral, economic, and US sanctions." Writing in Al Jazeera about this study, Jason Hickel, Dylan Sullivan, and Omer Tayyab estimated that unilateral sanctions imposed by the United States and European Union since 1970 were associated with approximately 38 million deaths worldwide, with more than half of the victims being children and the elderly, and that sanctions kill several times more people each year than die as direct casualties of war.
In 1958, the "University of Pittsburgh Health Center" comprised (1) Schools of Medicine, Dentistry, Pharmacy, Nursing, and the Graduate School of Public Health; (2) Presbyterian, Woman's, Children's, Eye and Ear, and Magee Hospitals; and (3) Falk Clinic, Western Psychiatric Institute and Clinic, Child Guidance Center, Salk Hall, and Central Blood Bank. Through the years, the university and the hospitals moved into an ever-closer alliance. In 1965, the university, Western Psychiatric Institute and Clinic which was managed by the School of Medicine, Presbyterian-University, Magee and Women's, Eye and Ear, and Children's Hospitals incorporated the University Health Center of Pittsburgh (UHCP). In 1969, Montefiore Hospital joined UHCP. In the 1970s, a new model of administration, in which clinical revenues were invested into research, was implemented at Western Psychiatric under the leadership of Thomas Detre. After becoming one of the largest recipients of National Institute of Health funding, Detre assumed leadership of all six university schools of health sciences in the early 1980s. Implementing the same administrative model in those units, the schools of health sciences and the medical center were ultimately transformed into one of the largest centers for biomedical research in the nation.
== Legal status == Difenoxin is a Schedule I drug by itself in the US; the combination with atropine is in the less-restrictive category Schedule IV on account of the adulterant (the practice of making opioids more easily available by including an abuse-deterring adulterating agent is standard practice in the United States). Pure difenoxin, in Schedule I, has a quota of 50 grammes, and an ACSCN of 9168. The combination of difenoxin and atropine, in Schedule IV, has the DEA ACSCN of 9167 and being in Schedule IV is not assigned an aggregate annual manufacturing quota.
Sources: en.wikipedia.org
=== Synthesis of urea === Although not usually isolated as such, the salt ammonium carbamate is produced on a large scale as an intermediate in the production of the commodity chemical urea from ammonia and carbon dioxide.
== Publication == In July 2016, Hillbilly Elegy was popularized by an interview with Vance in The American Conservative. The volume of requests briefly disabled the website. Halfway through August, The New York Times wrote that the title had remained in the top ten Amazon bestsellers since the interview's publication. Vance has credited his Yale contract law professor Amy Chua as the "authorial godmother" of the book, as she persuaded him to write the memoir.
In chemistry, diamondoids are generalizations of the carbon cage molecule known as adamantane (C10H16), the smallest unit cage structure of the diamond crystal lattice. Diamondoids also known as nanodiamonds or condensed adamantanes may include one or more cages (adamantane, diamantane, triamantane, and higher polymantanes) as well as numerous isomeric and structural variants of adamantanes and polymantanes. These diamondoids occur naturally in petroleum deposits and have been extracted and purified into large pure crystals of polymantane molecules having more than a dozen adamantane cages per molecule. These species are of interest as molecular approximations of the diamond cubic framework, terminated with C−H bonds.
conservative replication A hypothetical mode of DNA replication in which the two parental strands of the original double-stranded DNA molecule ultimately remain hybridized to each other at the end of the replication process, with the two daughter strands forming their own separate molecule; hence one molecule is composed of both of the starting strands while the other is composed of the two newly synthesized strands. This is in contrast to semiconservative replication, in which each molecule is a hybrid of one old and one new strand. See also dispersive replication.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.